1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
HLscience Co., Ltd.

HLscience Co., Ltd.

KKRX:239610
5,420.00
KRW
-10.00
(-0.18%)
-2,202.15EPS
27.15BMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14,825.43
9,935.76
7,493.72
12,065.29
24,143.12
28,517.52
20,105.25
10,072.13
5,019.78
3,469.36
3,280.17
2,049.35
Basic EPS, GAAP
2,209.52
1,474.29
920.95
2,044.76
3,716.19
3,916
2,608
304
-270
-1,547
-2,340
-2,189.37
Free Cash Flow per Basic Share
1,389.51
306.3
157.9
2,356.08
2,610.43
2,873.51
-1,593.95
-1,532.87
-868.9
-949.17
-1,486.44
-1,351.41
Dividend per Share
- -
- -
- -
190.46
285.74
403.53
385.2
400.65
- -
- -
- -
- -
Book Value per Share
2,690.71
9,295.59
10,001.12
11,855.59
15,285.31
19,170.38
20,443.63
20,353.27
20,110.42
18,563.75
16,219.79
15,362.72
Tangible Book Value per Share
2,609.03
9,185.52
9,892.88
11,734.8
15,157.49
19,035.37
20,187.37
20,013.91
19,789.65
18,300.08
16,033.89
15,202.47
Basic Weighted Avg Shares
2
4
5
5
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
23,705
40,926
40,197
64,108
128,261
143,036
104,375
52,758
25,587
17,664
16,706
10,440
Operating Margin (%)
12.55
16.76
13.27
19.11
18.47
16.52
14.15
-1.14
-18.34
-55.82
-66.15
-96.28
Depreciation Expense
221
256
483
612
653
685
809
1,652
2,408
2,559
2,601
2,335
Net Income, GAAP
3,533
6,073
4,940
10,865
19,742
19,642
13,539
1,592
-1,376
-7,877
-11,917
-11,153
Effective Tax Rate (%)
17.19
19.42
16.72
19.92
21.03
20.75
15.07
- -
- -
- -
- -
- -
Profit Margin (%)
14.9
14.84
12.29
16.95
15.39
13.73
12.97
3.02
-5.38
-44.59
-71.34
-106.83
Working Capital
6,536
38,142
36,103
46,483
57,524
68,649
61,760
33,393
35,621
31,198
30,356
27,413
LT Debt
- -
- -
- -
- -
56
23
3
- -
- -
450
- -
- -
Total Equity
14,528
50,189
53,136
62,988
81,210
95,840
107,413
104,302
102,593
94,627
82,770
78,384
Return on Invested Capital (%)
- -
16.55
8.47
16.53
24.86
20.33
12.14
- -
- -
- -
- -
- -
Return on Capital (%)
- -
18.77
9.56
18.71
27.37
22.17
13.32
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
18.77
9.56
18.71
27.38
22.19
13.33
1.51
-1.33
-8
-13.45
-13.3

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
41,202
38,044
27,145

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
32,431
31,246
29,409
Cash, Cash Equivalents & STI
26,323
24,932
24,158
Accounts Receivable, Net
286
663
655
Inventories
3,465
3,598
2,924
Total Current Liabilities
2,075
2,060
1,995
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.41%
-2.55%
-12.53%
Free Cash Flow
117.72%
-27.89%
56.65%
Net Income, GAAP
47.22%
43.57%
51.3%
Sales/Revenue/Turnover
7.76%
-32.88%
-5.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,132
5,291
3,495
3,747
17,664
2025
5,079
5,821
3,452
2,353
16,706
2026
2,135
2,500
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-321
-248
-198
-779.23
-1,547
2025
-487
-520
-436.21
-896.61
-2,340
2026
-364.6
-492
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hae-Yeon Lee
Full Time Employees
91
Sector
Health technology
Industry
Biotechnology
Address
Uiwang-si South Korea
IPO Date
Oct 28, 2016
Website
hlscience.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
HLscience Co., Ltd. is a South Korea-based biotechnology and healthcare company primarily engaged in the research, development, manufacture, and distribution of functional health foods, natural bioactive raw materials, cosmeceuticals, and therapeutic nutraceuticals. The company operates through several core product categories and business segments, including functional health supplements, comprising liver health formulas marketed under the Dr. Super Kan brand, cardiovascular and blood circulation supplements under the Dr. Cirkle brand, cellular and nutritional support products under Dr. Spirulina, female menopausal and vitality formulations based on proprietary pomegranate concentrates, joint and cartilage support products utilizing patented P-estro BL powder, metabolic and weight management solutions, and immune-support wellness formulations; proprietary health functional ingredients and individually recognized raw materials certified by the Ministry of Food and Drug Safety, featuring natural extracts for joint protection, skin hydration, anti-photoaging, and periodontal health such as HL-DENTI; functional cosmetics and cosmeceuticals, encompassing anti-aging skincare solutions, natural botanical ampoules, dermatological treatments, and specialized scalp and hair care products; and contract development and manufacturing organization services, providing customized formulation, natural extract processing, stability testing, and original equipment manufacturing and original design manufacturing solutions for domestic and international health supplement brands. The company distributes its products through domestic television home shopping networks, specialized direct-to-consumer e-commerce platforms, duty-free stores, pharmacies, major retail hypermarkets, and export channels across Asia, North America, and Europe. In recent operational and strategic developments, HLscience Co., Ltd. has expanded its pipeline of proprietary functional ingredients through advanced clinical trials in periodontal bone density, cognitive support, and muscle strength preservation; established collaborative research partnerships with academic medical centers and botanical research institutions to accelerate natural therapeutic development; optimized its advanced smart manufacturing facilities in compliance with current Good Manufacturing Practice standards to scale commercial contract manufacturing; and broadened its overseas market presence through international regulatory approvals, United States Food and Drug Administration facility registrations, and Halal certifications. Founded in 2000, HLscience Co., Ltd. is headquartered in Uiwang-si, Gyeonggi-do, South Korea.